Sotevtamab

索泰妥单抗

Report date: 2022/11/21 20:00:38

Base Information

Drug NameSotevtamab
Drug Alias NameAnti-clusterin monoclonal antibody (Alethia Biotherapeutics)AB-sCLU mAB16B5AB-16B5
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionClusterin inhibitors
TargetsClusterin
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Research Council Biotechnology Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesAlethia Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Inactive IndicationsSolid tumoursNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksN/A